“The high CD4/CD8 ratio and suppressed NK cell activity were artho improved by methyl-B12 treatment.” The Japanese researchers state: ease “We conclude that vitamin B12 acts as an immunomodulator for cellular immunity.”11 B12 was used successfully in the treatment of IgE-mediated skin disorders. The German researchers conclude that B12 (cobalamin) when applied to the skin one or more times per day exhibited artho “...excellent results in topical treatment of skin disorders and in particular of inflammatory and hyperproliferative skin ailments and/or cutaneous manifestations ease of illness which are immunologic in origin, e.g. psoriasis, atopic dermatitis, contact dermatitis, and other eczematous dermatitises...”12 Click here for Allergy medication online.

In January 1997, 62 subjects artho who had been the placebos in the 1995 study were invited to receive the vitamin ease B12. In June 1997, the 62 placebo subjects were artho sent a questionnaire asking: ease How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement artho and ease in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to artho the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or ease placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins artho for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy ease nose and antihistamine (chlorpheniramine) use. In the post-treatment period, artho the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10

Patients gave blood serum samples prior to the treatment in 1992 and one year later in 1993. They were immunoassayed for ease specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=34) had on average a greater reduction in IgE than the placebo group (n=33).7 On August 14, 1996 representatives of Broncorp, Inc. met with the Division Director, Dr. John Jenkins, and 14 other FDA officials of the Pulmonary Division at a PreNDA meeting. Dr. Mansfield artho made a presentation on the 1995 study data (n=165) from Oregon, ease Washington and Idaho. He noted that together the data failed to show statistical superiority of vitamin B12 on the primary endpoint. He noted that in Washington and Idaho, during the later part of the study, there artho was a drop in the pollen counts and marked ease improvements in symptoms in both the vitamin B12 and placebo groups. (This made a therapeutic benefit of the B12 treatment difficult to demonstrate.) But that the pollen counts in Oregon remained higher throughout the study and that the data from Oregon showed a significant difference between the active and placebo groups.8

©2003 www.asian-homeopathic-remedies.com All rights reserved.